These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31894036)

  • 21. Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
    Bao H; Gao HR; Pan ML; Zhao L; Sun HB
    Technol Health Care; 2021; 29(1):85-90. PubMed ID: 32925123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety assessment of alteplase in the treatment of stroke - gender differences.
    Lasek-Bal A; Puz P; Kazibutowska Z
    Neurol Res; 2014 Sep; 36(9):851-6. PubMed ID: 24620981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
    Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C;
    N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice.
    Dirks M; Niessen LW; van Wijngaarden J; Koudstaal PJ; Franke CL; van Oostenbrugge RJ; Dippel DW;
    Int J Stroke; 2012 Jun; 7(4):289-92. PubMed ID: 22168317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
    Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J;
    N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR.
    Toni D; Ahmed N; Anzini A; Lorenzano S; Brozman M; Kaste M; Mikulik R; Putaala J; Wahlgren N;
    Neurology; 2012 Mar; 78(12):880-7. PubMed ID: 22402853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of intravenous thrombolysis with alteplase in the treatment of ischaemic stroke in a rural hospital.
    Sobolewski P; Sledzińska-Dźwigał M; Szczuchniak W; Hatalska-Żerebiec R; Grzesik M; Sobota A
    Neurol Neurochir Pol; 2013; 47(4):310-8. PubMed ID: 23986420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study.
    Kim BJ; Han MK; Park TH; Park SS; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Lee J; Lee SJ; Ko Y; Park JM; Kang K; Cho YJ; Hong KS; Kim JT; Choi JC; Kim DE; Shin DI; Kim WJ; Lee J; Lee JS; Yoon BW; Gorelick PB; Bae HJ
    Stroke; 2015 Sep; 46(9):2541-8. PubMed ID: 26243232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
    Nakagawara J; Minematsu K; Okada Y; Tanahashi N; Nagahiro S; Mori E; Shinohara Y; Yamaguchi T;
    Stroke; 2010 Sep; 41(9):1984-9. PubMed ID: 20651262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors that influence clinicians' decisions to offer intravenous alteplase in acute ischemic stroke patients with uncertain treatment indication: Results of a discrete choice experiment.
    De Brún A; Flynn D; Ternent L; Price CI; Rodgers H; Ford GA; Rudd M; Lancsar E; Simpson S; Teah J; Thomson RG
    Int J Stroke; 2018 Jan; 13(1):74-82. PubMed ID: 28134031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Yamaguchi T; Mori E; Minematsu K; Nakagawara J; Hashi K; Saito I; Shinohara Y;
    Stroke; 2006 Jul; 37(7):1810-5. PubMed ID: 16763187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
    Külkens S; Hacke W
    Expert Rev Neurother; 2007 Jul; 7(7):783-8. PubMed ID: 17610385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
    Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Dewey HM; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Ang T; Miteff F; Levi CR; Rodrigues E; Zhao H; Salvaris P; Garcia-Esperon C; Bailey P; Rice H; de Villiers L; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Wong AA; Muller C; Coulthard A; Mitchell K; Clouston J; Mahady K; Field D; Ma H; Phan TG; Chong W; Chandra RV; Slater LA; Krause M; Harrington TJ; Faulder KC; Steinfort BS; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
    N Engl J Med; 2018 Apr; 378(17):1573-1582. PubMed ID: 29694815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
    Demaerschalk BM; Kleindorfer DO; Adeoye OM; Demchuk AM; Fugate JE; Grotta JC; Khalessi AA; Levy EI; Palesch YY; Prabhakaran S; Saposnik G; Saver JL; Smith EE;
    Stroke; 2016 Feb; 47(2):581-641. PubMed ID: 26696642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review.
    Sarmiento RJC; Diestro JDB; Espiritu AI; San Jose MCZ
    J Stroke Cerebrovasc Dis; 2019 Oct; 28(10):104290. PubMed ID: 31371140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke.
    Geng J; Song Y; Mu Z; Xu Q; Shi G; Sun Y; Chen Y; Lin Y; Pan Y; Yu L; Yang GY; Li Y
    Acta Neurochir Suppl; 2016; 121():269-75. PubMed ID: 26463960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.